# A Study of IRESSA in Relapsed and Refractory Small Cell Lung Cancer

> **NCT00298688** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 56 (—)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Gefitinib

## Key facts

- **NCT ID:** NCT00298688
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** —
- **Final completion:** 2007-03
- **Target enrollment:** 56 (—)
- **Last updated:** 2008-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00298688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00298688, "A Study of IRESSA in Relapsed and Refractory Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00298688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*